Dr Lookstein comments on paclitaxel

Adding to the current dialogue about paclitaxel in PAD, Dr. Robert Lookstein shares commentary on Eluvia.


Eluvia has the lowest drug dose density among all peripheral paclitaxel-based technologies


Eluvia’s controlled drug delivery ensures that the majority of drug is transferred to the lesion rather than downstream

Eluvia is efficient and effective

Eluvia has been shown to be endothelialized within 90 days post-implant2

1. Peter A. Schneider, MD, LINC 2017
2. Internal preclinical testing data on file. 


Imperial Trials table
Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.